Comprehensive Hemophilia Management: Leveraging Collaborative Care Strategies and Resources – Web Activity

• Release Date: February 1, 2015
• Expiration Date: August 31, 2016
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with (IE 6 and up, Firefox, Safari)

DISTINGUISHED FACULTY

Peg Geary, MA, MBA, MPH, LCSW, CCM Clinical Hemophilia Social Worker UMass Memorial Hospital, New England Hemophilia Center Click here for biography

Sue Geraghty, RN, MBA (Retired) Formerly: HTC Nurse Coordinator University of Colorado Hemophilia and Thrombosis Center University of Colorado Health Sciences Center Click here for biography

Marc Gilgannon, PT Lead Therapist University of Virginia Children's Hospital Click here for biography Patrick Lynch A Patient with Hemophilia Executive Producer, Believe Digi Click here for biography Michael D. Tarantino, MD Professor, Department of Pediatrics and Department of Medicine University of Illinois College of Medicine at Peoria Medical Director Bleeding and Clotting Disorders Institute Click here for biography

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Discuss the impact of hemophilia with and without inhibitors on clinical, economic, and humanistic outcomes
• Assess current and emerging hemophilia therapies for children and adults, with and without inhibitors
• Employ collaborative care strategies and resources, including HTCs, to improve care coordination for health plan patients with hemophilia
• Recommend hemophilia management policies and protocols to optimize patient outcomes in a managed care and/or specialty pharmacy setting
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with hemophilia including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes require a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans, and employers in meeting clinical and/or financial goals. This enduring activity will emphasize the need for well-coordinated treatment management, the importance of understanding effective ways of using available treatments, and the importance of collaboration among all stakeholders.

ACCREDITATION

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, National Hemophilia Foundation, and Impact Education, LLC.  The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0809-9999-15-002-H01-P, Application

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education
Credit Designation
This educational activity for 1.3 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 1, 2015 through August 31, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.